Recently, it was described that ARFGAP1 might act as a critical regulator of mechanistic target of rapamycin complex 1 (mTORC1) by inhibiting lysosomal localization and activation of mTORC1, resulting in decreased cell growth; therefore, these results propose its potential for cancer therapy [74]. This evidence concerns the gene ARFGAP1 and cancer.